Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 7/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.90 |
| ▸ | DPP4 | P27487 | 1/20 | 0.90 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.90 |
| ▸ | RELA | Q04206 | 1/20 | 0.90 |
| ▸ | MAPT | P10636 | 6/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.82 |
| ▸ | TP53 | P04637 | 2/20 | 0.82 |
| ▸ | ATM | Q13315 | 1/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.82 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.81 |
| ▸ | MEN1 | O00255 | 4/20 | 0.81 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.81 |
| ▸ | HPGD | P15428 | 2/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.81 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.81 |
| ▸ | USP2 | O75604 | 1/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flavokawain A SCHEMBL25209870 | 1.00 | ABCG2 (1.00) | ABCG2NFKB1DPP4NFKB2RELA | |
| Flavokawain A SCHEMBL29349587 | 1.00 | ABCG2 (1.00) | ABCG2NFKB1DPP4NFKB2RELA | |
| Flavokawain A SCHEMBL2289188 | 1.00 | ABCG2 (1.00) | ABCG2NFKB1DPP4NFKB2RELA | |
| Flavokawain C SCHEMBL30384247 | 0.94 | NFKB1 (1.00) | ABCG2NFKB1DPP4NFKB2RELA | |
| Flavokawain C SCHEMBL25201341 | 0.94 | NFKB1 (1.00) | ABCG2NFKB1DPP4NFKB2RELA | |
| Flavokawain C SCHEMBL144230 | 0.94 | NFKB1 (1.00) | ABCG2NFKB1DPP4NFKB2RELA | |
| Flavokawain C SCHEMBL144231 | 0.94 | NFKB1 (1.00) | ABCG2NFKB1DPP4NFKB2RELA | |
| SCHEMBL30383887 | 0.93 | ABCG2 (0.87) | ABCG2NFKB1DPP4NFKB2RELA | |
| SCHEMBL2286230 | 0.93 | ABCG2 (0.87) | ABCG2NFKB1DPP4NFKB2RELA | |
| SCHEMBL2286236 | 0.93 | ABCG2 (0.87) | ABCG2NFKB1DPP4NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113956226-A | Method for synthesizing carvachin | 南京科技职业学院 | 2022-01-21 | — | — | CN | claimed |
| US-7326734-B2 | Treatment of bladder and urinary tract cancers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-02-05 | — | — | US | claimed |
| US-20040259813-A1 | Treatment of bladder and urinary tract cancers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-12-23 | — | — | US | claimed |
| US-20260048027-A1 | METHYLATED PHLORETIN ANALOGS AS INHIBITORS OF SGLT2 | NESTLE SA (CH) | 2026-02-19 | — | — | US | disclosed |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4598515-A1 | PHYTOCHEMICAL FORMULATIONS FOR TREATING STRESS AND ANXIETY | GBS Global Biopharma, Inc. (CA) | 2025-08-13 | — | — | EP | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250090565-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YewSavin, Inc. (US) | 2025-03-20 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| WO-2024054462-A1 | PHYTOCHEMICAL FORMULATIONS FOR TREATING STRESS AND ANXIETY | GBS GLOBAL BIOPHARMA, INC. (CA) | 2024-03-14 | — | — | WO | disclosed |
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | EASTMAN CHEMICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
| WO-2007115181-A2 | COMPOUNDS EXHIBITING EFFLUX INHIBITOR ACTIVITY AND COMPOSITIONS AND USES THEREOF | EASTMAN CHEMICAL COMPANY (US) | 2007-10-11 | — | — | WO | disclosed |
| US-20040259813-A1 | Treatment of bladder and urinary tract cancers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-12-23 | — | — | US | disclosed |
| US-20040259813-A1 | Treatment of bladder and urinary tract cancers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-12-23 | — | — | US | disclosed |
| US-5234951-A | Anti-ulcer agent comprising chalcone derivative | TSUMURA JUNTENDO, INC. (JP) | 1993-08-10 | — | — | US | disclosed |
| US-5106871-A | Reduced side effects | TSUMURA & CO. (JP) | 1992-04-21 | — | — | US | disclosed |
| EP-0292576-A1 | ANTI-ULCEROUS AGENT CONTAINING CHALCONE DERIVATIVE AS EFFECTIVE INGREDIENT AND NOVEL CHALCONE DERIVATIVES | TSUMURA & CO. (JP) | 1988-11-30 | — | — | EP | disclosed |
| US-4605674-A | VIRICIDES | HOFFMANN-LA ROCHE INC. (US) | 1986-08-12 | — | — | US | disclosed |
| US-4327088-A | ANTIVIRAL AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1982-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254859-A1 | Compounds exhibiting efflux inhibitor activity and composition and uses thereof | ABCC4, NCOA4, NR4A3 | ABCG2 5/4885NFKB1 1115/4885DPP4 1159/4885 |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | ABCG2 1606/4885NFKB1 1669/4885DPP4 4226/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | ABCG2 3622/4885NFKB1 2437/4885DPP4 3670/4885 |
| US-20260048027-A1 | METHYLATED PHLORETIN ANALOGS AS INHIBITORS OF SGLT2 | SLC5A2, SLC5A1, SLC2A1 | ABCG2 954/4885NFKB1 4036/4885DPP4 302/4885 |
| US-20040259813-A1 | Treatment of bladder and urinary tract cancers | KLK5, KLK4, KLK6 | ABCG2 1850/4885NFKB1 2579/4885DPP4 2900/4885 |
| US-20250090565-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, TFPI, SERPINE1 | ABCG2 3458/4885NFKB1 2413/4885DPP4 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.